QATARDEBATE
Under the patronage of HE Sheikha Hind bint Hamad Al Thani , Vice Chairperson and CEO of Qatar Foundation for Education, Science and Community Development, the third International Schools Arabic Debating Championship organized by QatarDebate , concluded. The championship took place at the Qatar National Convention Centre (QNCC) from April 10-13, 2016, and included 54 teams from Arab and non-Arab countries.
This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20160416005018/en/
The Qatari team took first place in this year’s edition of the International Schools Arabic Debating Championship, followed by the Syrian Arab Republic team and the Tunisian team in second and third place respectively.
In her address at the closing ceremony, Dr. Hayat Abdullah Maarafi , Executive Director of QatarDebate center, welcomed their Excellencies, guests and participants and expressed her pleasure to see such a great crowd in the Doha, “brought together by the Arabic language, despite their differences,” she said.
Dr. Maarafi hailed the instrumental role of the debate, which contributed to strengthening the Arabic language and enriched our culture with diverse new ideas. She said: "The championship was the meeting place of heroes, and a melting pot to celebrate the differences and diversity of cultures and civilizations. It is a living proof that the Arabic language needs no defender; it can accommodate to all dialects and thoughts, while emphasizing the need to look for similarities in order to coexist peacefully, with respect and reconciliation. It also prompts us to reject the impurities that have been introduced by multiculturalism, to prepare future leaders capable of assuming the task of building nations."
Dr. Maarafi also appointed Professor Salem Al Shammakhi, from the Sultanate of Oman and Professor Thaer Farhat, from the Hashemite Kingdom of Jordan, as new ambassadors for QatarDebate, in recognition of their role in spreading the culture of debating.
In conclusion, she extended her heartfelt thanks to HE Sheikha Hind bint Hamad Al Thani, Vice Chairperson and CEO of Qatar Foundation for sponsoring the event; to Mr Fahad Saad Al Qahtani, President Community Development at Qatar Foundation, for his support and presence at the closing ceremony, and to H.E Minister of Education and Higher Education, Secretary General of the Supreme Education Council Dr. Mohammad bin Abdul Wahed Al-Hammadi.
Towards the end of the ceremony, Mr. Al Qahtani took to the stage to honor the winners, along with H. E Dr. Abdul Aziz bin Abdullah bin Turki Al Subaie, Chairman of the Board of Trustees of the World Organization for Renaissance of Arabic Language (WORAL), and Dr. Hayat Abdullah Maarafi, Executive Director of QatarDebate center.
The World Organization for Renaissance of Arabic Language (WORAL) was also honored during the ceremony. H. E Dr. Abdul Aziz bin Abdullah bin Turki Al Subaie received the award, in appreciation for organizing the events held on the sidelines of the championship.
*Source: ME NewsWire
View source version on businesswire.com: http://www.businesswire.com/news/home/20160416005018/en/
Contact:
QatarDebate
Khaled Al-Ibrahim, +974-55-83-4445
kibrahim@qf.org.qa
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
4Moving Biotech Enrolls First Patient in Phase 2a Trial of 4P004, a Potential First-in-Class GLP-1 Therapy for Knee Osteoarthritis16.7.2025 07:00:00 CEST | Press release
- First patient enrolled in INFLAM MOTION, a global randomized Phase 2a trial including 129 knee osteoarthritis patients - 4P004 to be evaluated over 3 months for dual efficacy: symptom relief and synovial health improvement via contrast-enhanced MRI - Topline results expected in the second half of 2026 4Moving Biotech (4MB), a spin-off of 4P-Pharma dedicated to developing first-in-class treatments that modify the natural course of knee osteoarthritis (OA), today announced that the first patient has been enrolled in Phase 2a clinical trial, INFLAM MOTION. The study will evaluate 4P004, an intra-articular GLP-1 analog, as a potential first-in-class therapeutic candidate for knee osteoarthritis. INFLAM MOTION is a multicenter, randomized, double-blind, placebo-controlled Phase 2a trial planned to be conducted across Europe, the United States, and Canada. A total of 129 patients worldwide diagnosed with knee OA will be enrolled to evaluate, for the first time in humans, the efficacy of 4P
Belkin Achieves Qi2.2 Certification for Its Upcoming Products, Unlocking the Future of 25W Wireless Charging15.7.2025 19:06:00 CEST | Press release
With Qi2.2 certification, Belkin reinforces its commitment to quality, safety, and performance for the next generation of wireless charging Belkin, a leading consumer electronics brand for over 40 years, today announced it has received official Qi2.2 certification from the Wireless Power Consortium (WPC) for its upcoming products. As one of the first accessory brands to deliver Qi2.2-certified devices, Belkin is helping bring the next generation of wireless charging to market – enabling faster wireless charging speeds, broader compatibility, and improved performance for consumers. Belkin’s close partnership with the WPC since 2015 has been instrumental in bringing these advancements to consumers. As an early adopter and long-time contributor to WPC standards, Belkin was selected as one of a small group of trusted manufacturers to test and certify Qi2.2 products ahead of the broader industry rollout. All Belkin products undergo rigorous safety, quality, and performance testing. The comp
Cessna Grand Caravan EX to Feature New Executive Interior Options, Expanding Opportunities for Elevated Missions15.7.2025 18:05:00 CEST | Press release
The legendary Cessna Grand Caravan EX will now feature three new executive interior schemes for customers to select when designing their aircraft cabin. The Lunar, Obsidian and Saddle Sport interiors join the existing Canyon and Savanna schemes, providing a broader range of standard choices. The new interior options are available to customers starting this month and allow them to further tailor the interior of their aircraft based on their personal preference or mission. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250715021096/en/ Cessna Grand Caravan EX to feature new executive interior options, expanding opportunities for elevated missions (Photo Credit: Textron Aviation) The Cessna Grand Caravan EX is designed and manufactured by Textron Aviation Inc., a Textron Inc. (NYSE:TXT) company. Premium versions of each of the new interiors are also available, featuring quilted seat stitching and plush carpet, providing an elev
7 Million Tokens Sells Out in less than One Hour—$MBG Token Pre-Sale Shatters Expectations15.7.2025 17:27:00 CEST | Press release
MultiBank Group, the world’s largest and most regulated financial derivatives institution, has set a new benchmark in digital asset launches. The Group’s $MBG Token Pre-Sale sold out in less than one hour with all 7 million tokens fully subscribed across MultiBank.io and Uniswap. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250715055611/en/ The Group’s $MBG Token Pre-Sale sold out in less than one hour with all 7 million tokens fully subscribed across MultiBank.io and Uniswap. Commenting on the success of the Pre-Sale, Naser Taher, Founder and Chairman of MultiBank Group, said: “The sell-out of our initial $MBG Token offering in less than one hour is a decisive validation of our vision. In a market saturated with speculation, the response we received confirms that institutional-grade transparency, regulatory integrity, and asset-backed value are what investors are now demanding. $MBG is here for the long term, reflecting t
First Patient Enrolled in National Cancer Institute’s Vanguard Study Evaluating Guardant Health’s Shield Multi-Cancer Detection Test15.7.2025 17:01:00 CEST | Press release
Study addressing feasibility of using multi-cancer detection tests in future trials aims to enroll up to 24,000 participantsShield MCD reviewed by FDA as part of NCI’s investigational device exemption (IDE) Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that patient enrollment has begun in the National Cancer Institute (NCI)’s Vanguard Study to evaluate emerging multi-cancer detection (MCD) technology. Guardant’s Shield™ MCD test was selected for use in the four-year study, which aims to enroll up to 24,000 patients and evaluate the use of MCD tests—blood tests that can screen for several types of cancer simultaneously—in future randomized controlled trials. Guardant’s Shield MCD test was chosen for the study based on the overall performance of its Shield platform in detecting 10 cancer types, including lung, breast, colorectal, prostate, bladder, ovarian, pancreatic, esophageal, liver and gastric. The data were presented at the 2025 American
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom